Nicotinamide Mononucleotide (NMN)
What it is
NAD+ precursor one step closer to NAD+ than NR; aimed at restoring NAD+ pools.
What the evidence says
Like NR, human trials show NMN (150-1200 mg/day) safely and dose-dependently raises blood NAD+. Functional benefits are small and inconsistent: a 12-week RCT in older men (250 mg/day) raised NAD+ and showed only nominal gait-speed and grip-strength improvements with no change in muscle mass. A systematic review of 10 RCTs (437 patients) found physical-performance improvements were non-significant overall. NMN is well tolerated, but evidence for anti-aging outcomes remains preliminary.
250-900 mg/day; ~600 mg/day cited as a practical upper-efficacy point for NAD+/performance
Educational summary of doses studied — not a recommendation. Talk to a clinician before starting any supplement.
Sources (2)
- Chronic nicotinamide mononucleotide supplementation elevates blood NAD levels and alters muscle function in healthy older men — npj Aging (PMID: 35927255) (2022)
- Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials — Cureus (2024)
Educational summary of published research, checked against primary sources and linked inline. Not medical advice; supplements are not FDA-evaluated to treat disease. See our editorial policy.